Cargando…

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney

Detalles Bibliográficos
Autor principal:	Heerspink, Hiddo J L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Ndt Digest
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035671/ https://www.ncbi.nlm.nih.gov/pubmed/30789206 http://dx.doi.org/10.1093/ndt/gfz033

Ejemplares similares

MicroRNAs as non-invasive biomarkers of renal disease
por: Connor, Katie L, et al.
Publicado: (2019)

Diagnosing renal involvement in connective tissue disease: interpretation of anti-nuclear autoantibody tests
por: Nimmo, Ailish, et al.
Publicado: (2019)

Is there a role for proteomics in diabetic renal disease?
por: Currie, Gemma, et al.
Publicado: (2020)

Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies
por: Pickup, Luke C, et al.
Publicado: (2019)

Artificial intelligence: is there a potential role in nephropathology?
por: Hermsen, Meyke, et al.
Publicado: (2020)

How to evaluate phosphate control in patients on dialysis
por: Martin, Kevin J
Publicado: (2021)

Bioimpedance in CKD: an untapped resource?
por: Mayne, Kaitlin J, et al.
Publicado: (2022)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

The SARS-CoV-2 main protease as drug target
por: Ullrich, Sven, et al.
Publicado: (2020)

The signal peptide as a new target for drug design
por: Lumangtad, Liezel A., et al.
Publicado: (2020)

Digest: What keeps sexual signals honest? A general new explanation
por: Haaland, Thomas Ray
Publicado: (2022)

Digest: Stable phenotypes, fluid genotypes: how stochasticity impacts network evolution and speciation
por: James, Maddie E., et al.
Publicado: (2022)

SFPH proteins as therapeutic targets for a myriad of diseases
por: Wang, Dong, et al.
Publicado: (2020)

Cryo-EM as a powerful tool for drug discovery
por: Van Drie, John H, et al.
Publicado: (2020)

Digest: A synergistic approach explains the evolutionary connection between brain size and longevity(*)
por: Silva, Willian T.A.F.
Publicado: (2020)

Digest: Great tits and their ticks: Life‐history traits affect tick fitness
por: Matson, Kevin D., et al.
Publicado: (2022)

Digest: Frequent hybridization in Darevskia rarely leads to the evolution of asexuality
por: Kong, Sungsik
Publicado: (2022)

Digest: Recent movement of a flicker hybrid zone
por: Ottenburghs, Jente
Publicado: (2022)

Digest: The evolution of social behavior and its effect on aggressiveness and reproduction
por: Silva, Willian T. A. F.
Publicado: (2022)

Digest: Deprivation of parental care reveals the value of sibling cooperation in burying beetles
por: Sun, Syuan‐Jyun, et al.
Publicado: (2022)

Digest: Following clines along an Amazonian hybrid zone(*)
por: Ottenburghs, Jente
Publicado: (2022)

Digest: On the origin of a possible hybrid species
por: Stankowski, Sean
Publicado: (2022)

Digest: Evolution of plasticity and its potential role in the decline of specialists
por: Zhou, Sharon, et al.
Publicado: (2022)

How does diabetes cause susceptibility to COVID-19 in the kidney: new clues provided by organoids
por: Xia, Yun, et al.
Publicado: (2022)

Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
por: Alhenc-Gelas, Francois, et al.
Publicado: (2020)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
por: Neuen, Brendon L., et al.
Publicado: (2020)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

Repurposing UDCA, an FXR Inhibitor, to Prevent SARS-Cov-2 Infection
por: Prayitno, Khairunnadiya, et al.
Publicado: (2023)

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Highlights From the Latest in Diabetes Research
Publicado: (2012)

Highlights From the Latest in Diabetes Research
Publicado: (2012)

Highlights From the Latest in Diabetes Research
Publicado: (2012)

Highlights From the Latest in Diabetes Research
Publicado: (2012)

Highlights From the Latest in Diabetes Research
Publicado: (2012)

Highlights From the Latest in Diabetes Research
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_d8onumr28aflhe9l1c9pr1cg6c